Core Viewpoint - Renhe Pharmaceutical (000650) indicates that there are currently no specific drugs or vaccines for the prevention of rhinovirus, emphasizing the importance of cutting off droplet and contact transmission, personal and environmental protection, and enhancing immunity [1] Company Products - The company offers several products for symptomatic relief from rhinovirus infections, including Ibuprofen capsules, Compound Paracetamol and Amantadine capsules, and Strong Loquat capsules [1]

Group 1 - The flu activity in China is on the rise, with a peak expected between mid-December and early January, leading to increased demand for antiviral and symptomatic treatment drugs, especially among children [1] - Bank securities report indicates that antiviral drugs are the main treatment method, with good expected efficacy; various traditional Chinese medicines and antipyretics are also available to alleviate symptoms during the illness [1] - Data from Meituan shows that since November, the overall order volume for specific flu medications has increased by over 100%, with orders for Oseltamivir granules rising by over 85% and for Baloxavir increasing by over 110% [1] Group 2 - Hainan Huhuwawa Pharmaceutical Group's Oseltamivir products have performed well, with capsules approved for production and stable market supply for the prevention and treatment of influenza A and B [3] - The company has developed a dry suspension that received drug registration certification in September, addressing dosage challenges for young children aged two and above [3] - The core product, Pediatric Lung Heat Cough and Asthma Granules, has been included in national treatment guidelines and health insurance directories, enhancing its market presence [3] Group 3 - Huhuwawa Pharmaceutical emphasizes research and innovation as a core driver for development, continuously enhancing R&D efforts in the pediatric medication sector [4] - The company has increased investment in R&D for pediatric drugs, with ongoing projects targeting infectious diseases, functional dyspepsia, allergic diseases, and adenoid hypertrophy [4]

Core Viewpoint - West Point Pharmaceutical (301130.SZ) has announced its existing products, including a mature anti-influenza drug, compound acetaminophen and amantadine capsules, and an antiviral tablet expected to be approved for market in 2025 for treating upper respiratory infections and influenza [1] Group 1 - The company has a mature anti-influenza product, compound acetaminophen and amantadine capsules [1] - An antiviral tablet is anticipated to receive approval for market launch in 2025, aimed at treating upper respiratory infections and influenza [1] - The research project on "the intervention effect of Ruixiangsu on mouse models of human diseases" has shown safety and efficacy results for Ruixiangsu in treating viral pneumonia [1] Group 2 - The company has obtained a patent for "the application of Ruixiangsu in the preparation of drugs for treating viral pneumonia" [1]

Core Viewpoint - The company, Renhe Pharmaceutical, confirmed the availability of several influenza treatment medications and emphasized its commitment to ensuring stable production and supply to meet market demand [2]. Product Information - The company currently sells influenza treatment medications including Oseltamivir Phosphate Capsules, Ibuprofen Sustained-Release Capsules, Amoxicillin Capsules, Compound Aminophenol and Amantadine Capsules, Strong Loquat Capsules, and Pediatric Acetaminophen Granules [2]. - In addition to these, the company offers various medications for symptoms related to influenza-like illnesses, providing consumers with multiple options for symptomatic relief [2]. Supply Assurance - The company has prioritized the supply of these influenza-related medications to ensure they meet market demand effectively [2].

Core Viewpoint - The company has existing flu medication products and is developing new antiviral treatments, indicating a strong position in the respiratory infection market [2]. Product Overview - The company currently markets a mature flu medication, Compound Acetaminophen and Amantadine Capsules [2]. - An antiviral tablet is expected to receive approval for market launch in 2025, aimed at treating upper respiratory infections and influenza [2]. Research and Development - The company is conducting research on "Rui Xiang Su" for its effects on viral pneumonia in mouse models, showing safety and efficacy [2]. - A patent has been obtained for the application of "Rui Xiang Su" in the preparation of drugs for treating viral pneumonia [2]. - The company is the sole producer and seller of "Rui Xiang Su" capsules in China [2].